Coexpression of the XXXX gene product, p185HER-2, and @entity470 , p170EGF-R, on @entity43 and normal tissues.

@entity43 @entity5 @entity470 @entity19601 @entity1722
Monoclonal antibodies (MAbs) and immunoconjugates reactive with different antigens expressed by neoplastic cells can inhibit @entity5 growth. Use of these agents in combination with one another or with chemotherapy can exert additive or synergistic cytotoxicity against @entity5 cells. An augmented therapeutic activity with favorable therapeutic index might be attained when coexpression is observed on @entity5 cells, but not in normal tissues. In this study frozen sections of 19 @entity43 (2 stage I, 10 stage III, 2 stage IV, and 5 recurrent), as well as 29 normal tissues, were evaluated by immunohistochemistry using 11 distinct MAbs against @entity1722 / @entity19601 antibodies against @entity470 /p170 to assess coexpression of these receptors. @entity1722 / @entity19601 expression was detected in 5 to 100% of @entity43 and 0 to 50% of normal @entity43 , depending on the antibody used. @entity470 /p170 expression was detected in approximately 70% of @entity5 and 40% of normal ovaries by both antibodies. Coexpression of @entity19601 and p170 was observed in 47-68% of @entity43 and 9-18% of normal ovarian epithelial specimens depending upon the combination of antibodies used. Staining of 273 specimens from 29 normal tissues indicated that coexpression of @entity1722 and @entity470 is rare. Normal tissues that coexpressed both receptors in > or =50% of the cases included cervix, endometrium, esophagus, skin, and prostate. These data confirm that @entity1722 and @entity470 are more frequently expressed in advanced @entity43 than in normal ovarian epithelium and a significant fraction of these @entity5 coexpress both @entity1722 and @entity470 .
